ESR1 and breast carcinoma: But how we negate ER negativity and endocrine resistance in breast cancers is questionable, to answer that two important approaches are considered: (1) understanding the origin of heterogeneity and ER negativity and (2) characterization of molecular regulators of endocrine resistance.